This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cozzi M, Monteduro D, Esposito RA, Spooner K, Fraser-Bell S, Staurenghi G, et al. Lesion area progression in eyes with neovascular age-related macular degeneration treated using a proactive or a reactive regimen. Eye. 2024;38:161–7.
Veritti D, Sarao V, Soppelsa V, Danese C, Chhablani J, Lanzetta P. Managing neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression. J Clin Med. 2022;11:325.
Frades I, Matthiesen R. Overview on techniques in cluster analysis. Bioinform Methods Clin Res. 2010;593:81–107.
Mauschitz MM, Finger RP. Age-related macular degeneration and cardiovascular diseases: revisiting the common soil theory. Asia Pac J Ophthalmol. 2022;11:94–9.
Keenan TD, Agrón E, Mares J, Clemons TE, van Asten F, Swaroop A, et al. Agerelated eye disease studies (AREDS) 1 and 2 research groups. adherence to the mediterranean diet and progression to late age-related macular degeneration in the age-related eye disease studies 1 and 2. Ophthalmology. 2020;127:1515–28.
Author information
Authors and Affiliations
Contributions
Concept, writing, editing, and approval of the final version of the manuscript: AFNJ, AMMB, OS, FJBE.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Niño-Joya, A.F., Martínez-Blanco, A.M., Salamanca, O. et al. Comment on: “Lesion area progression in eyes with neovascular age-related macular degeneration treated using a proactive or a reactive regimen”. Eye (2024). https://doi.org/10.1038/s41433-024-03063-8
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41433-024-03063-8